Öz
Ebola hastalığı (EBOD), Filoviridae ailesine ait Orthoebolavirus türlerinin neden olduğu, yüksek mortaliteli ağır seyirli viral bir hastalıktır. 15 Mayıs 2026’da Demokratik Kongo Cumhuriyeti’nin Ituri Eyaleti’nde Bundibugyo virüsüne (BDBV) bağlı yeni bir salgının başlaması ve Uganda’da sınır ötesi olgular saptanması, EBOD’un küresel halk sağlığı güncelliğini yeniden ön plana taşımıştır. Bu derleme; EBOD’un güncel terminoloji ve sınıflandırması, patogenezi, bulaş yolları, klinik ve laboratuvar bulguları, tanı testleri, vaka tanımları, tedavi yaklaşımları, enfeksiyon önlem ve kontrolü, temaslı takibi, aşılama stratejileri ile uzun dönem sekeller konularını kapsamlı biçimde ele almaktadır. Mevcut lisanslı aşı ve monoklonal antikor tedavilerinin yalnızca Orthoebolavirus zairense için onaylı olması, BDBV kaynaklı salgınlarda tedavi seçeneklerini kısıtlamaktadır. Pan-filovirüs tedavi ve aşı geliştirme çalışmalarının hızlandırılması, erken tanı kapasitesinin güçlendirilmesi ve enfeksiyon kontrol altyapısının iyileştirilmesi öncelikli hedefler olmaya devam etmektedir.
Anahtar Kelimeler:
Ebola hastalığı, Bundibugyo virüsü, Orthoebolavirus, filovirüs, salgın
Kaynaklar
1
International Committee on Taxonomy of Viruses. Genus: Orthoebolavirus. Last accessed date: 2026 May 17. Available from: https://ictv.global/report/chapter/filoviridae/filoviridae/orthoebolavirus
2
World Health Organization. Ebola disease. Last accessed date: 2026 Jul 28. Available from: https://www.who.int/news-room/fact-sheets/detail/ebola-disease
3
Mohd OB, Sawaqed S, Kundu M, Ghannam RA, Mohd AB, AlSamhori JF, Musallam OK, Altiti A, Hasan H, Khaity A. The development of Ebola virus outbreaks: a review of epidemiological trends, clinical features, and treatment advances. Cureus. 2024;16:e74078.
4
Centers for Disease Control and Prevention. History of Ebola outbreaks. Last accessed date: 2026 Jul 28. Available from: https://www.cdc.gov/ebola/outbreaks/index.html
5
UpToDate. Epidemiology and pathogenesis of Ebola disease. Last accessed date: 2026 Jul 28. Available from: https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-ebola-disease
6
Izudi J, Bajunirwe F. Case fatality rate for Ebola disease, 1976-2022: A meta-analysis of global data. J Infect Public Health. 2024;17:25-34.
7
World Health Organization. Ebola vaccines. Last accessed date: 2026 Jul 28. Available from: https://www.who.int/news-room/questions-and-answers/item/ebola-vaccines
8
European Medicines Agency. Ebola. Last accessed date: 2026 Jul 28. Available from: https://www.ema.europa.eu/en/human-regulatory-overview/public-health-threats/ebola
9
Mulangu S, Dodd LE, Davey RT Jr, Tshiani Mbaya O, Proschan M, Mukadi D, Lusakibanza Manzo M, Nzolo D, Tshomba Oloma A, Ibanda A, Ali R, Coulibaly S, Levine AC, Grais R, Diaz J, Lane HC, Muyembe-Tamfum JJ, Sivahera B, Camara M, Kojan R, Walker R, Dighero-Kemp B, Cao H, Mukumbayi P, Mbala-Kingebeni P, Ahuka S, Albert S, Bonnett T, Crozier I, Duvenhage M, Proffitt C, Teitelbaum M, Moench T, Aboulhab J, Barrett K, Cahill K, Cone K, Eckes R, Hensley L, Herpin B, Higgs E, Ledgerwood J, Pierson J, Smolskis M, Sow Y, Tierney J, Sivapalasingam S, Holman W, Gettinger N, Vallée D, Nordwall J. A randomized, controlled trial of Ebola virus disease therapeutics. N Engl J Med. 2019;381:2293-2303.
10
Group PIW, Team MPIS, Davey RT Jr, Dodd L, Proschan MA, Neaton J, Neuhaus Nordwall J, Koopmeiners JS, Beigel J, Tierney J, Lane HC, Fauci AS, Massaquoi MBF, Sahr F, Malvy D. A randomized, controlled trial of ZMapp for Ebola virus ınfection. N Engl J Med. 2016;375:1448-1456.
11
World Health Organization. Therapeutics for Ebola virus disease. 2022. Last accessed date: 2026 Jul 28. Available from: https://www.who.int/publications/i/item/9789240055742
12
World Health Organization. Technical Advisory Group on therapeutics prioritization for Bundibugyo virus disease: meeting report, 20 and 26 May 2026. 2026. Last accessed date: 2026 Jul 28. Available from: https://www.who.int/publications/i/item/B09767
13
Kuang E, Cross RW, McCavitt-Malvido M, Abelson DM, Borisevich V, Stuart L, Agans KN, Mlakar N, Marimuthu A, Deer DJ, Shestowsky WS, Kim D, Geisbert JB, Zeitlin L, Moyer CL, Roy CJ, Geisbert TW, Bornholdt ZA. Reversion of Ebolavirus disease from a single ıntramuscular ınjection of a Pan-Ebolavirus ımmunotherapeutic. Pathogens. 2022;11:655.
14
Cross RW, Bornholdt ZA, Prasad AN, Woolsey C, Borisevich V, Agans KN, Deer DJ, Abelson DM, Kim DH, Shestowsky WS, Campbell LA, Bunyan E, Geisbert JB, Dobias NS, Fenton KA, Porter DP, Zeitlin L, Geisbert TW. Combination therapy with remdesivir and monoclonal antibodies protects nonhuman primates against advanced Sudan virus disease. JCI Insight. 2022;7.
15
World Health Organization. WHO Director-General’s opening remarks at the media briefing—16 July 2026. 2026. Last accessed date: 2026 Jul 28. Available from: https://www.who.int/news-room/speeches/item/who-director-general-s-opening-remarks-at-the-media-briefing---16-july-2026
16
World Health Organization. Patient enrolment begins in a scientific trial to identify the first effective treatments for Bundibugyo virus disease. 2026. Last accessed date: 2026 Jul 28. Available from: https://www.who.int/news/item/02-07-2026-patient-enrolment-begins-in-a-scientific-trial-to-identify-the-first-effective-treatments-for-bundibugyo-virus-disease
17
Levine CB, Mire CE, Geisbert TW. Comparison of Zaire and Bundibugyo Ebolavirus polymerase complexes and susceptibility to antivirals through a newly developed Bundibugyo minigenome system. J Virol. 2021;95:e0064321.
18
Nash RK, Bhatia S, Morgenstern C, Doohan P, Jorgensen D, McCain K, McCabe R, Nikitin D, Forna A, Cuomo-Dannenburg G, Hicks JT, Sheppard RJ, Naidoo T, van Elsland S, Geismar C, Rawson T, Leuba SI, Wardle J, Routledge I, Fraser K, Imai-Eaton N, Cori A, Unwin HJT. Ebola virus disease mathematical models and epidemiological parameters: a systematic review. Lancet Infect Dis. 2024;24:e762-e773.
19
Jaspard M, Mulangu S, Juchet S, Serra B, Dicko I, Lang HJ, Baka BM, Komanda GM, Katsavara JM, Kabuni P, Mambu FM, Isnard M, Vanhecke C, Letord A, Dieye I, Patterson-Lomba O, Mbaya OT, Isekusu F, Mangala D, Biampata JL, Kitenge R, Kinda M, Anglaret X, Muyembe JJ, Kojan R, Ezzedine K, Malvy D. Development of the PREDS score to predict in-hospital mortality of patients with Ebola virus disease under advanced supportive care: Results from the EVISTA cohort in the Democratic Republic of the Congo. EClinicalMedicine. 2022;54:101699.
20
Binagwaho A, Mathewos K. Infectious disease outbreaks highlight gender inequity. Nat Microbiol. 2022;7:361-362.
21
Olivero J, Fa JE, Real R, Márquez AL, Farfán MA, Vargas JM, Gaveau D, Salim MA, Park D, Suter J, King S, Leendertz SA, Sheil D, Nasi R. Recent loss of closed forests is associated with Ebola virus disease outbreaks. Sci Rep. 2017;7:14291.
22
Gonzalez A, Nikparvar B, Matson MJ, Baranowski K, Seifert SN, Ross HD, Munster V, Bharti N. Links between infrastructure for human movement and early Ebola outbreak trajectories. Sci Rep. 2026;16:3920.
23
World Health Organization. One Health joint plan of action 2022-2026: working together for the health of humans, animals, plants and the environment. 2022. Last accessed date: 2026 Jul 27. Available from: https://www.who.int/publications/i/item/9789240059139
24
Centers for Disease Control and Prevention. Ebola outbreak: current situation. 2026. Last accessed date: 2026 May 21. Available from: https://www.cdc.gov/ebola/situation-summary/index.html
25
Centers for Disease Control and Prevention. Ebola disease outbreak in the Democratic Republic of the Congo and Uganda. 2026. Last accessed date: 2026 May 31. Available from: https://www.cdc.gov/han/php/notices/han00530.html
26
World Health Organization. Ebola disease caused by Bundibugyo virus, Democratic Republic of the Congo and Uganda. 2026. Last accessed date: 2026 Jul 28. Available from: https://www.who.int/emergencies/disease-outbreak-news/item/2026-DON613
27
Africa Centres for Disease Control and Prevention. Bundibugyo virus disease outbreak situational report, July 21, 2026. 2026. Last accessed date: 2026 Jul 28. Available from: https://khub.africacdc.org/records/resource/bundibugyo-virus-disease-outbreak-situational-report-july-21-2026
28
Coalition for Epidemic Preparedness Innovations. CEPI fast-tracks three Bundibugyo ebolavirus vaccine candidates. 2026. Last accessed date: 2026 Jul 28. Available from: https://cepi.net/cepi-fast-tracks-three-bundibugyo-ebolavirus-vaccine-candidates
29
World Health Organization Regional Office for Africa. Bundibugyo Ebola virus: continental preparedness and response plan, June-November 2026. 2026. Last accessed date: 2026 Jul 27. Available from: https://www.afro.who.int/publications/bundibugyo-ebola-virus-continental-preparedness-and-response-plan-june-november-2026
30
Malvy D, McElroy AK, de Clerck H, Günther S, van Griensven J. Ebola virus disease. Lancet. 2019;393:936-948.
31
Bodmer BS, Wendt L, Dupré J, Groseth A, Hoenen T. Antiviral defense against filovirus infections: targets and evasion mechanisms. Future Microbiol. 2025;20:573-587.
32
Centers for Disease Control and Prevention. Ebola disease basics. Last accessed date: 2026 Jul 28. Available from: https://www.cdc.gov/ebola/about/index.html
33
Lanini S, Portella G, Vairo F, Kobinger GP, Pesenti A, Langer M, Kabia S, Brogiato G, Amone J, Castilletti C, Miccio R, Capobianchi MR, Strada G, Zumla A, Di Caro A, Ippolito G. Relationship between viremia and specific organ damage in Ebola patients: A cohort study. Clin Infect Dis. 2018;66:36-44.
34
Vetter P, Fischer WA 2nd, Schibler M, Jacobs M, Bausch DG, Kaiser L. Ebola Virus Shedding and Transmission: Review of Current Evidence. J Infect Dis. 2016;214(Suppl 3):177-184.
35
Public Health Agency of Canada. Ebola disease prevention, monitoring and surveillance recommendations. Last accessed date: 2026 May 18. Available from: https://www.canada.ca/en/public-health/services/catmat/ebola-virus-disease-preventive-measures-monitoring-surveillance-travellers.html
36
Reichler MR, Bruden D, Thomas H, Erickson BR, Knust B, Duffy N, Klena J, Hennessy T. Ebola Patient Virus Cycle Threshold and Risk of Household Transmission of Ebola Virus. J Infect Dis. 2020;221:707-714.
37
Lyman M, Mpofu JJ, Soud F, Oduyebo T, Ellington S, Schlough GW, Koroma AP, McFadden J, Morof D. Maternal and perinatal outcomes in pregnant women with suspected Ebola virus disease in Sierra Leone, 2014. Int J Gynaecol Obstet. 2018;142:71-77.
38
Kamali A, Jamieson DJ, Kpaduwa J, Schrier S, Kim M, Green NM, Ströher U, Muehlenbachs A, Bell M, Rollin PE, Mascola L. Pregnancy, Labor, and Delivery after Ebola Virus Disease and Implications for Infection Control in Obstetric Services, United States. Emerg Infect Dis. 2016;22:1156-1161.
39
World Health Organization. Infection prevention and control guideline for Ebola and Marburg diseases. Last accessed date: 2026 Jul 28. Available from: https://www.who.int/publications/i/item/9789240111332
40
Jacob ST, Crozier I, Fischer WA 2nd, Hewlett A, Kraft CS, Vega MA, Soka MJ, Wahl V, Griffiths A, Bollinger L, Kuhn JH. Ebola virus disease. Nat Rev Dis Primers. 2020;6:13.
41
Velásquez GE, Aibana O, Ling EJ, Diakite I, Mooring EQ, Murray MB. Time From Infection to Disease and Infectiousness for Ebola Virus Disease, a Systematic Review. Clin Infect Dis. 2015;61:1135-1140.
42
Timothy JWS, Hall Y, Akoi-Boré J, Diallo B, Tipton TRW, Bower H, Strecker T, Glynn JR, Carroll MW. Early transmission and case fatality of Ebola virus at the index site of the 2013-16 west African Ebola outbreak: a cross-sectional seroprevalence survey. Lancet Infect Dis. 2019;19:429-438.
43
Glynn JR, Bower H, Johnson S, Houlihan CF, Montesano C, Scott JT, Semple MG, Bangura MS, Kamara AJ, Kamara O, Mansaray SH, Sesay D, Turay C, Dicks S, Wadoum REG, Colizzi V, Checchi F, Samuel D, Tedder RS. Asymptomatic infection and unrecognised Ebola virus disease in Ebola-affected households in Sierra Leone: a cross-sectional study using a new non-invasive assay for antibodies to Ebola virus. Lancet Infect Dis. 2017;17:645-653.
44
Xu Z, Jin B, Teng G, Rong Y, Sun L, Zhang J, Du N, Liu L, Su H, Yuan Y, Chen H. Epidemiologic characteristics, clinical manifestations, and risk factors of 139 patients with Ebola virus disease in western Sierra Leone. Am J Infect Control. 2016;44:1285-1290.
45
Centers for Disease Control and Prevention. Clinical features of Ebola disease. Last accessed date: 2026 Jul 28. Available from: https://www.cdc.gov/ebola/hcp/clinical-signs/index.html
46
Kortepeter MG, Bausch DG, Bray M. Basic clinical and laboratory features of filoviral hemorrhagic fever. J Infect Dis. 2011;204(Suppl 3):810-816.
47
UpToDate. Clinical manifestations and diagnosis of Ebola disease. Last accessed date: 2026 May 18. Available from: https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-ebola-disease
48
Rojek AM, Salam A, Ragotte RJ, Liddiard E, Elhussain A, Carlqvist A, Butler M, Kayem N, Castle L, L’O, Stepniewska K, Horby PW. A systematic review and meta-analysis of patient data from the West Africa 2013-16 Ebola virus disease epidemic. Clin Microbiol Infect. 2019;25:1307-1314.
49
Nsio J, Ardiet DL, Coulborn RM, Grellety E, Albela M, Grandesso F, Kitenge R, Ngwanga DL, Matady B, Manangama G, Mossoko M, Ngwama JK, Mbala P, Luquero F, Porten K, Ahuka-Mundeke S. Differential symptomology of possible and confirmed Ebola virus disease infection in the Democratic Republic of the Congo: a retrospective cohort study. Lancet Infect Dis. 2023;23:91-102.
50
Rojek A, Fieggen J, Apiyo P, Caluwaerts S, Fowler RA, Kaleebu P, Kojan R, Lado M, Lambe T, Dunning J, Horby P. Ebola disease: bridging scientific discoveries and clinical application. Lancet Infect Dis. 2025;25:e165-e176.
51
BAŞTUĞ A, BODUR H. Ebola viral disease: What should be done to combat the epidemic in 2014? Turk J Med Sci. 2015;45:1-5.
52
World Health Organization. Optimized supportive care for Ebola virus disease: clinical management standard operating procedures. Last accessed date: 2026 Jul 28. Available from: https://www.who.int/publications/i/item/9789241515894
53
Centers for Disease Control and Prevention. Viral hemorrhagic fever VHF 2025 case definition. Last accessed date: 2026 Jul 28. Available from: https://ndc.services.cdc.gov/case-definitions/viral-hemorrhagic-fever-vhf/
54
Centers for Disease Control and Prevention. Signs and symptoms of Ebola disease [Internet]. Atlanta (GA): Centers for Disease Control and Prevention; [cited 2026 May 22]. Available from: https://www.cdc.gov/ebola/signs-symptoms/index.html
55
World Health Organization. Ebola virus disease outbreak toolbox. Last accessed date: 2026 May 18. Available from: https://www.who.int/emergencies/outbreak-toolkit/disease-outbreak-toolboxes/ebola-and-marburg-virus-outbreak-toolbox
56
Republic of Türkiye Ministry of Health, Department of Zoonotic and Vector-Borne Diseases. Ebola Virüs Hastalığı Bilgilendirme ve Vaka Yönetim Rehberi. Ankara: Ministry of Health; 2019. Last accessed date: 2026 Jul 28. Available from: https://hsgm.saglik.gov.tr/tr/deneme4/306-ebola-virus-hastaligi-bilgilendirme-ve-vaka-yonetim-rehberi.html
57
World Health Organization. Diagnostic testing for Ebola and Marburg virus diseases: interim guidance, 20 December 2024. Last accessed date: 2026 May 18. Available from: https://www.who.int/publications/i/item/B09221
58
Boggild AK, Esposito DH, Kozarsky PE, Ansdell V, Beeching NJ, Campion D, Castelli F, Caumes E, Chappuis F, Cramer JP, Gkrania-Klotsas E, Grobusch MP, Hagmann SH, Hynes NA, Lim PL, López-Vélez R, Malvy DJ, Mendelson M, Parola P, Sotir MJ, Wu HM, Hamer DH. Differential diagnosis of illness in travelers arriving from Sierra Leone, Liberia, or Guinea: a cross-sectional study from the GeoSentinel Surveillance Network. Ann Intern Med. 2015;162:757-764.
59
Johnston V, Stockley JM, Dockrell D, Warrell D, Bailey R, Pasvol G, Klein J, Ustianowski A, Jones M, Beeching NJ, Brown M, Chapman AL, Sanderson F, Whitty CJ. Fever in returned travellers presenting in the United Kingdom: recommendations for investigation and initial management. J Infect. 2009;59:1-18.
60
Centers for Disease Control and Prevention. Post-travel evaluation of the ill traveler. CDC Yellow Book. Last accessed date: 2026 Jul 28. Available from: https://www.cdc.gov/yellow-book/hcp/post-travel-evaluation/post-travel-evaluation-of-the-ill-traveler.html
61
Centers for Disease Control and Prevention. Post-travel evaluation to rule out viral special pathogen infection. Last accessed date: 2026 Jul 28. Available from: https://www.cdc.gov/yellow-book/hcp/post-travel-evaluation/post-travel-evaluation-to-rule-out-viral-special-pathogen-infection.html
62
Shears P, Garavan C. The 2018/19 Ebola epidemic the Democratic Republic of the Congo DRC: epidemiology, outbreak control, and conflict. Infect Prev Pract. 2020;2:100038.
63
Bettini A, Lapa D, Garbuglia AR. Diagnostics of Ebola virus. Front Public Health. 2023;11:1123024.
64
Centers for Disease Control and Prevention. VHF clinical specimen packaging and shipping. Last accessed date: 2026 May 20. Available from: https://www.cdc.gov/viral-hemorrhagic-fevers/php/laboratories/specimen-packing.html
65
Muzembo BA, Kitahara K, Ohno A, Ntontolo NP, Ngatu NR, Okamoto K, Miyoshi SI. Rapid diagnostic tests versus RT-PCR for Ebola virus infections: a systematic review and meta-analysis. Bull World Health Organ. 2022;100:447-458.
66
Mukadi-Bamuleka D, Bulabula-Penge J, De Weggheleire A, Jacobs BKM, Edidi-Atani F, Mambu-Mbika F, Mbala-Kingebeni P, Makiala-Mandanda S, Faye M, Diagne CT, Diagne MM, Faye O, Kajihara M, Faye O, Takada A, Sall AA, Muyembe-Tamfum JJ, van Griensven J, Ariën KK, Ahuka-Mundeke S. Field performance of three Ebola rapid diagnostic tests used during the 2018-20 outbreak in the eastern Democratic Republic of the Congo: a retrospective, multicentre observational study. Lancet Infect Dis. 2022;22:891-900.
67
Rosello A, Mossoko M, Flasche S, Van Hoek AJ, Mbala P, Camacho A, Funk S, Kucharski A, Ilunga BK, Edmunds WJ, Piot P, Baguelin M, Muyembe Tamfum JJ. Ebola virus disease in the Democratic Republic of the Congo, 1976-2014. Elife. 2015;4:e09015.
68
Lindblade KA, Kateh F, Nagbe TK, Neatherlin JC, Pillai SK, Attfield KR, Dweh E, Barradas DT, Williams SG, Blackley DJ, Kirking HL, Patel MR, Dea M, Massoudi MS, Wannemuehler K, Barskey AE, Zarecki SL, Fomba M, Grube S, Belcher L, Broyles LN, Maxwell TN, Hagan JE, Yeoman K, Westercamp M, Forrester J, Mott J, Mahoney F, Slutsker L, DeCock KM, Nyenswah T. Decreased Ebola Transmission after Rapid Response to Outbreaks in Remote Areas, Liberia, 2014. Emerg Infect Dis. 2015;21:1800-1807.
69
World Health Organization. Case definition recommendations for Ebola or Marburg virus diseases: interim guideline. Last accessed date: 2026 Jul 28. Available from: https://www.who.int/publications/i/item/WHO-EVD-CaseDef-14-1
70
Haaskjold YL, Bolkan HA, KØ K, Jongopi J, Lundeby KM, Mellesmo S, Garcés PS, Jøsendal O, Å P, Svensen E, Fuentes LM, Kamara AS, Riera M, Arranz J, Roberts DP, Stamper PD, Austin P, Moosa AJ, Marke D, Hassan S, Eide GE, Å B, Blomberg B. Clinical Features of and Risk Factors for Fatal Ebola Virus Disease, Moyamba District, Sierra Leone, December 2014-February 2015. Emerg Infect Dis. 2016;22:1537-1544.
71
Caleo G, Theocharaki F, Lokuge K, Weiss HA, Inamdar L, Grandesso F, Danis K, Pedalino B, Kobinger G, Sprecher A, Greig J, Di Tanna GL. Clinical and epidemiological performance of WHO Ebola case definitions: a systematic review and meta-analysis. Lancet Infect Dis. 2020;20:1324-1338.
72
Jain V, Charlett A, Brown CS. Meta-analysis of predictive symptoms for Ebola virus disease. PLoS Negl Trop Dis. 2020;14:e0008799.
73
European Centre for Disease Prevention and Control. Ebola disease interim case definition for reporting in the EU/EEA. Last accessed date: 2026 Jun 15. Available from: https://www.ecdc.europa.eu/en/topics-z/ebola-disease/surveillance-and-updates/ebola-outbreak-democratic-republic-congo-and-3
74
UK Health Security Agency. Epidemiological case definitions for Ebola disease and Marburg disease. Last accessed date: 2026 May 30. Available from: https://www.gov.uk/guidance/epidemiological-case-definitions-for-ebola-disease-and-marburg-disease
75
Lamontagne F, Fowler RA, Adhikari NK, Murthy S, Brett-Major DM, Jacobs M, Uyeki TM, Vallenas C, Norris SL, Fischer WA 2nd, Fletcher TE, Levine AC, Reed P, Bausch DG, Gove S, Hall A, Shepherd S, Siemieniuk RA, Lamah MC, Kamara R, Nakyeyune P, Soka MJ, Edwin A, Hazzan AA, Jacob ST, Elkarsany MM, Adachi T, Benhadj L, Clément C, Crozier I, Garcia A, Hoffman SJ, Guyatt GH. Evidence-based guidelines for supportive care of patients with Ebola virus disease. Lancet. 2018;391:700-708.
76
Uyeki TM, Mehta AK, Davey RT Jr, Liddell AM, Wolf T, Vetter P, Schmiedel S, Grünewald T, Jacobs M, Arribas JR, Evans L, Hewlett AL, Brantsaeter AB, Ippolito G, Rapp C, Hoepelman AI, Gutman J. Clinical Management of Ebola Virus Disease in the United States and Europe. N Engl J Med. 2016;374:636-646.
77
Centers for Disease Control and Prevention. Clinical guidance for Ebola disease. Last accessed date: 2026 May 18. Available from: https://www.cdc.gov/ebola/hcp/clinical-guidance/
78
Group PIS, Sneller MC, Reilly C, Badio M, Bishop RJ, Eghrari AO, Moses SJ, Johnson KL, Gayedyu-Dennis D, Hensley LE, Higgs ES, Nath A, Tuznik K, Varughese J, Jensen KS, Dighero-Kemp B, Neaton JD, Lane HC, Fallah MP. A Longitudinal Study of Ebola Sequelae in Liberia. N Engl J Med. 2019;380:924-934.
79
Fausther-Bovendo H, Kobinger G. The road to effective and accessible antibody therapies against Ebola virus. Curr Opin Virol. 2022;54:101210.
80
Woolsey C, Cross RW, Chu VC, Prasad AN, Agans KN, Borisevich V, Deer DJ, Harrison MB, Martinez JK, Dobias NS, Fenton KA, Cihlar T, Nguyen AQ, Babusis D, Bannister R, Vermillion MS, Geisbert TW. The oral drug obeldesivir protects nonhuman primates against lethal Ebola virus infection. Sci Adv. 2025;11:eadw0659.
81
Wirchnianski AS, Nyakatura EK, Herbert AS, Kuehne AI, Abbasi SA, Florez C, Storm N, McKay LGA, Dailey L, Kuang E, Abelson DM, Wec AZ, Chakraborti S, Holtsberg FW, Shulenin S, Bornholdt ZA, Aman MJ, Honko AN, Griffiths A, Dye JM, Chandran K, Lai JR. Design and characterization of protective pan-ebolavirus and pan-filovirus bispecific antibodies. PLoS Pathog. 2024;20:e1012134.
82
Centers for Disease Control and Prevention. Infection prevention and control recommendations for patients in U.S. hospitals who are suspected or confirmed to have selected viral hemorrhagic fevers. Last accessed date: 2026 Jul 28. Available from: https://www.cdc.gov/viral-hemorrhagic-fevers/hcp/infection-control/index.html
83
Centers for Disease Control and Prevention. Public health management of people with suspected or confirmed VHFs or high-risk exposures. Last accessed date: 2026 May 18. Available from: https://www.cdc.gov/viral-hemorrhagic-fevers/php/public-health-strategy/people-with-suspected-or-confirmed-vhf-or-high-risk.html
84
Nyenswah T, Massaquoi M, Gbanya MZ, Fallah M, Amegashie F, Kenta A, Johnson KL, Yahya D, Badini M, Soro L, Pessoa-Silva CL, Roger I, Selvey L, VanderEnde K, Murphy M, Cooley LA, Olsen SJ, Christie A, Vertefeuille J, Navin T, McElroy P, Park BJ, Esswein E, Fagan R, Mahoney F, Centers for Disease Control and Prevention. Initiation of a ring approach to infection prevention and control at non-Ebola health care facilities - Liberia, January-February 2015. MMWR Morb Mortal Wkly Rep. 2015;64:505-508.
85
European Centre for Disease Prevention and Control. Risk assessment guidelines for infectious diseases transmitted on aircraft RAGIDA—Ebola disease update. Last accessed date: 2026 Jul 28. Available from: https://www.ecdc.europa.eu/en/publications-data/risk-assessment-guidelines-infectious-diseases-transmitted-aircraft-ragida-ebola
86
Centers for Disease Control and Prevention. Ebola vaccine administration. Last accessed date: 2026 Jul 29. Available from: https://www.cdc.gov/ebola/hcp/vaccines/ebola-vaccine-administration.html
87
United States Food and Drug Administration. ERVEBO. Last accessed date: 2026 Jul 29. Available from: https://www.fda.gov/vaccines-blood-biologics/ervebo
88
Kennedy SB, Bolay F, Kieh L, Grandits G, Badio M, Ballou R, Eckes R, Feinberg M, Follmann D, Grund B, Gupta S, Hensley L, Higgs E, Janosko K, Johnson M, Kateh F, Logue J, Marchand J, Monath T, Nason M, Nyenswah T, Roman F, Stavale E, Wolfson J, Neaton JD, Lane HC. Phase 2 Placebo-Controlled Trial of Two Vaccines to Prevent Ebola in Liberia. N Engl J Med. 2017;377:1438-1447.
89
Team PS, Kieh M, Richert L, Beavogui AH, Grund B, Leigh B, D’Ortenzio E, Doumbia S, Lhomme E, Sow S, Vatrinet R, Roy C, Kennedy SB, Faye S, Lees S, Millimouno NP, Camara AM, Samai S, Deen GF, Doumbia M, Espérou H, Pierson J, Watson-Jones D, Diallo A, Wentworth D, McLean C, Simon J, Wiedemann A, Dighero-Kemp B, Hensley L, Lane HC, Levy Y, Piot P, Greenwood B, Chêne G, Neaton J, Yazdanpanah Y. Randomized Trial of Vaccines for Zaire Ebola Virus Disease. N Engl J Med. 2022;387:2411-2424.
90
Malenfant JH, Joyce A, Choi MJ, Cossaboom CM, Whitesell AN, Harcourt BH, Atmar RL, Villanueva JM, Bell BP, Hahn C, Loehr J, Davey RT, Sprecher A, Kraft CS, Shoemaker T, Montgomery JM, Helfand R, Damon IK, Frey SE, Chen WH. Use of Ebola Vaccine: Expansion of Recommendations of the Advisory Committee on Immunization Practices To Include Two Additional Populations - United States, 2021. MMWR Morb Mortal Wkly Rep. 2022;71:290-292.
91
Henao-Restrepo AM, Camacho A, Longini IM, Watson CH, Edmunds WJ, Egger M, Carroll MW, Dean NE, Diatta I, Doumbia M, Draguez B, Duraffour S, Enwere G, Grais R, Gunther S, Gsell PS, Hossmann S, Watle SV, Kondé MK, Kéïta S, Kone S, Kuisma E, Levine MM, Mandal S, Mauget T, Norheim G, Riveros X, Soumah A, Trelle S, Vicari AS, Røttingen JA, Kieny MP. Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ça Suffit!). Lancet. 2017;389:505-518. Erratum in: Lancet. 2017;389:504.
92
Muyembe JJ, Pan H, Peto R, Diallo A, Touré A, Mbala-Kingebene P, Bateyi Mustafa SH, Tambwe N, Mulangu S, Ahuka-Mundeke S, Mukamba Musenga E, Enwere G, Gsell PS, Longini IM, Riveros Balta X, Roberts CH, Marks M, Yao MNK, Gueye AS, Fall IS, Salama P, Ryan MJ, Henao-Restrepo AM. Ebola Outbreak Response in the DRC with rVSV-ZEBOV-GP Ring Vaccination. N Engl J Med. 2024;391:2327-2336.
93
World Health Organization. WHO emergency guidance on the use of licensed Ebola virus vaccine during Bundibugyo virus disease outbreaks, 28 May 2026. Last accessed date: 2026 Jul 29. Available from: https://www.who.int/publications/i/item/B09772
94
Diallo B, Sissoko D, Loman NJ, Bah HA, Bah H, Worrell MC, Conde LS, Sacko R, Mesfin S, Loua A, Kalonda JK, Erondu NA, Dahl BA, Handrick S, Goodfellow I, Meredith LW, Cotten M, Jah U, Guetiya Wadoum RE, Rollin P, Magassouba M, Malvy D, Anglaret X, Carroll MW, Aylward RB, Djingarey MH, Diarra A, Formenty D, Keïta S, Günther S, Rambaut A, Duraffour S. Resurgence of Ebola Virus Disease in Guinea Linked to a Survivor With Virus Persistence in Seminal Fluid for More Than 500 Days. Clin Infect Dis. 2016;63:1353-1356.
95
Mate SE, Kugelman JR, Nyenswah TG, Ladner JT, Wiley MR, Cordier-Lassalle T, Christie A, Schroth GP, Gross SM, Davies-Wayne GJ, Shinde SA, Murugan R, Sieh SB, Badio M, Fakoli L, Taweh F, de Wit E, van Doremalen N, Munster VJ, Pettitt J, Prieto K, Humrighouse BW, Ströher U, DiClaro JW, Hensley LE, Schoepp RJ, Safronetz D, Fair J, Kuhn JH, Blackley DJ, Laney AS, Williams DE, Lo T, Gasasira A, Nichol ST, Formenty N, Kateh FN, De Cock KM, Bolay F, Sanchez-Lockhart M, Palacios G. Molecular Evidence of Sexual Transmission of Ebola Virus. N Engl J Med. 2015;373:2448-2454.
96
Salata C, Calistri A, Alvisi G, Celestino M, Parolin C, Palù G. Ebola Virus Entry: From Molecular Characterization to Drug Discovery. Viruses. 2019;11.
97
Kaweesa RE, Katende JS, Wayesu RR, Ntabadde AD, Opio S, Kato L, Oluka GK, Nambi R, Tumusiime RA, Team F, Kaleebu P, Lutwama JJ, Serwanga J. Resilience and residuals beyond containment - The hidden burden of Bundibugyo Ebola virus survivorship sixteen years on: A cross-sectional observational study. New Microbes New Infect. 2026;69:101685.
98
Almeida-Pinto F, Pinto R, Rocha J. Navigating the Complex Landscape of Ebola Infection Treatment: A Review of Emerging Pharmacological Approaches. Infect Dis Ther. 2024;13:21-55.
99
World Health Organization. TAG-TP statement on immunomodulators and host-directed therapies for Bundibugyo virus disease. Last accessed date: 2026 Jul 28. Available from: https://www.who.int/news/item/26-06-2026-tag-tp-statement-on-immunomodulators-and-host-directed-therapies-for-bundibugyo-virus-disease
100
Médecins Sans Frontières Access Campaign. Ensuring access to new treatments for Ebola virus disease. Last accessed date: 2026 Jul 28. Available from: https://msfaccess.org/ensuring-access-new-treatments-ebola-virus-disease
101
Torreele E, Boum Y 2nd, Adjaho I, Alé FGB, Issoufou SH, Harczi G, Okonta C, Olliaro P. Breakthrough treatments for Ebola virus disease, but no access-what went wrong, and how can we do better? Lancet Infect Dis. 2023;23:e253-e258.
102
Jaspard M, Juchet S, Serra B, Mayoum B, Kanta IM, Camara MS, Mbala P, Kojan R, Malvy D. Post-exposure prophylaxis following high-risk contact with Ebola virus, using immunotherapies with monoclonal antibodies, in the eastern Democratic Republic of the Congo: an emergency use program. Int J Infect Dis. 2021;113:166-167.
